23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Viridian Therapeutics, Inc. › 2025-2026

Viridian Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Viridian Therapeutics, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Reported items
  • 238Asset managers, any item
  • 1,899Fund votes
  • June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 4 items on Viridian Therapeutics, Inc.’s Form 8-K, filed June 3, 2026: 2 elected · 2 passed (calculated).

Dissent

Notable dissent: 1 director (16.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Caligan Partners (13F, 1.9%, as of September 30, 2026) · Tang Capital (13F, 1.6%, as of September 30, 2026)

Explore Viridian Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Viridian Therapeutics, Inc.

These tallies are Viridian Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Viridian Therapeutics, Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Tomas Kiselak 72,363,500---- 14,475,6466,733,104 83%Elected—
Elect Director: Jennifer K. Moses 86,378,842---- 460,3046,733,104 99.5%Elected—
2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 92,866,008512,582193,660 ---- 99.5%Passed (calculated)—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers 83,512,0863,113,724213,336 --6,733,104 96%Passed (calculated)—

Source: Viridian Therapeutics, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.

How asset managers voted at the Viridian Therapeutics, Inc. 2025-2026 meeting

238 asset managers disclosed a vote on at least one Viridian Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Viridian Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Jennifer K. Moses

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 86,378,842WITHHELD: 460,304
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jennifer K. Moses

Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer K. Moses”): 86,378,842 for, 460,304 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 36,614,137 for, 38,566 withheld, 1 abstained.

FOR
FOR: 36,614,137ABSTAIN: 1WITHHOLD: 38,566
Largest asset managers voting on “To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until ” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,760,6970 13,349For
BlackRock3,585,8610 00For
State Street2,984,2810 00For
T. Rowe Price2,198,7810 00For
Charles Schwab728,1760 00For
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford535,6950 00For
Federated Hermes437,4090 00For
Victory Capital349,6350 00For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI170,5970 00For
Dimensional166,4530 00For
Principal160,4130 00For
Goldman Sachs152,5840 00For
Bridge Builder Trust148,8380 00For
Brighthouse124,0830 00For
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual111,4850 00For
CLEARWATER INVESTMENT TRUST100,9770 00For
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Elect Director: Tomas Kiselak

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD
FOR: 72,363,500WITHHELD: 14,475,646
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Tomas Kiselak

Viridian Therapeutics, Inc.’s own tally for this item (“Elect Director: Tomas Kiselak”): 72,363,500 for, 14,475,646 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 30,829,621 for, 5,823,066 withheld, 17 abstained.

FORWITHHOLD
FOR: 30,829,621ABSTAIN: 17WITHHOLD: 5,823,066
Largest asset managers voting on “To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until ” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,760,6810 173,349For
BlackRock3,585,8610 00For
State Street8,7990 02,975,482Withhold
T. Rowe Price2,198,7810 00For
Charles Schwab00 0728,176Withhold
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford00 0535,695Withhold
Federated Hermes00 0437,409Withhold
Victory Capital345,9230 03,712For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI00 0170,597Withhold
Dimensional00 0166,453Withhold
Principal160,4130 00For
Goldman Sachs142,6280 09,956Mixed
Bridge Builder Trust19,7400 0129,098Mixed
Brighthouse124,0830 00For
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual00 0111,485Withhold
CLEARWATER INVESTMENT TRUST00 0100,977Withhold
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Approval, on an advisory basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 83,512,086AGAINST: 3,113,724

Prior year: 77.8% for (June 20, 2025 meeting) ▲ 18.6 pts

Details: description as filed, official tally, votes by 238 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.

Viridian Therapeutics, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 83,512,086 for, 3,113,724 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 64 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,760,6933,354 00For
BlackRock3,585,8610 00For
State Street2,983,1891,092 00For
T. Rowe Price2,198,7810 00For
Charles Schwab728,1760 00For
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford535,6950 00For
Federated Hermes437,4090 00For
Victory Capital349,6350 00For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI170,5970 00For
Dimensional166,4530 00For
Principal160,4130 00For
Goldman Sachs152,5840 00For
Bridge Builder Trust148,8380 00For
Brighthouse124,0830 00For
Northwestern Mutual111,4850 00For
CLEARWATER INVESTMENT TRUST100,9770 00For
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For
Russell Investments82,1770 00For

Fund voting reports, all 64 managers: 36,487,409 for, 5,677 against, 35,217 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 194 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity14,697,6440 00For
State Street4,638,9542,123 00For
Fairmount Funds Management LLC3,914,4580 00For
Venrock Adviser, LLC3,760,0280 00For
T. Rowe Price3,350,5310 00For
BlackRock3,033,33110,929 00For
Wellington2,500,1520 00For
GEODE CAPITAL MANAGEMENT, LLC2,338,1510 00For
Novo Holdings A/S2,000,0000 00For
Deep Track Capital, LP1,892,2810 00For
Paradigm Biocapital Advisors LP1,662,3580 00For
AllianceBernstein1,315,5420 00For
Citadel1,060,2780 00For
Fisher Asset Management, LLC697,319250,419 00Mixed
DE Shaw822,5730 00For
RICE HALL JAMES & ASSOCIATES, LLC749,8480 00For
Charles Schwab738,3090 00For
Candriam S.C.A.0711,739 00Against
Eversept Partners, LP693,2510 00For
Vanguard687,6080 00For
PERCEPTIVE ADVISORS LLC686,6690 00For
Federated Hermes656,4334,970 00For
MPM BioImpact LLC612,7630 00For
BALYASNY ASSET MANAGEMENT L.P.598,9650 00For
Northern Trust551,3975,721 00For

Institutional-manager reports, all 194 managers: 59,520,359 for, 2,141,349 against, 99 abstained, 18,613 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 233 asset managers

Description as filed by funds: To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 64 asset managers voting on “To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
Vanguard00 00--
BlackRock00 00--
State Street00 00--
T. Rowe Price00 00--
Charles Schwab00 00--
AllianceBernstein00 00--
TIAA00 00--
Hartford00 00--
Federated Hermes00 00--
Victory Capital00 00--
First Trust00 00--
Voya00 00--
Equitable00 00--
SEI00 00--
Dimensional00 00--
Principal00 00--
Goldman Sachs00 00--
Bridge Builder Trust00 00--
Brighthouse124,0830 00For
Northwestern Mutual00 00--
CLEARWATER INVESTMENT TRUST00 00--
JPMorgan00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
Russell Investments00 00--

Fund voting reports, all 64 managers: 124,083 for, 35,217 abstained, 36,190,378 1 year, 178,489 3 year, 135 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 188 asset managers voting on “To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
State Street00 00--
Fairmount Funds Management LLC00 00--
Venrock Adviser, LLC00 00--
T. Rowe Price00 00--
BlackRock00 00--
Wellington00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Novo Holdings A/S00 00--
Deep Track Capital, LP00 00--
Paradigm Biocapital Advisors LP00 00--
AllianceBernstein00 00--
Citadel00 00--
Fisher Asset Management, LLC00 00--
DE Shaw00 00--
RICE HALL JAMES & ASSOCIATES, LLC00 00--
Charles Schwab00 00--
Candriam S.C.A.00 00--
Vanguard00 00--
PERCEPTIVE ADVISORS LLC686,6690 00For
Federated Hermes00 00--
MPM BioImpact LLC00 00--
BALYASNY ASSET MANAGEMENT L.P.00 00--
Northern Trust00 00--
Nuveen00 00--

Institutional-manager reports, all 188 managers: 752,848 for, 344 against, 59,918,530 1 year, 85,828 3 year, 8,194 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 92,866,008AGAINST: 512,582

Prior year: 99.2% for (June 20, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Viridian Therapeutics, Inc.’s own tally for this item (“2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 92,866,008 for, 512,582 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 36,617,368 for, 119 against, 35,217 abstained.

FOR
FOR: 36,617,368AGAINST: 119ABSTAIN: 35,217
Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEA” at Viridian Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,739,8810 00For
Vanguard5,764,0461 00For
BlackRock3,585,8610 00For
State Street2,984,163118 00For
T. Rowe Price2,198,7810 00For
Charles Schwab728,1760 00For
AllianceBernstein699,1970 00For
TIAA537,5640 00For
Hartford535,6950 00For
Federated Hermes437,4090 00For
Victory Capital349,6350 00For
First Trust301,0860 00For
Voya228,9250 00For
Equitable189,0130 00For
SEI170,5970 00For
Dimensional166,4530 00For
Principal160,4130 00For
Goldman Sachs152,5840 00For
Bridge Builder Trust148,8380 00For
Brighthouse124,0830 00For
Yiheng Capital Management, L.P.117,2760 00For
Northwestern Mutual111,4850 00For
CLEARWATER INVESTMENT TRUST100,9770 00For
JPMorgan98,9350 00For
QUANTITATIVE MASTER SERIES LLC93,3010 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Largest Viridian Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,074,740 shares outstanding at the time of that meeting.

Fund voting reports: top Viridian Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 15.27%
2Vanguard 5.59%
3BlackRock 3.48%
4State Street 2.90%
5T. Rowe Price 2.13%
6Charles Schwab 0.71%
7AllianceBernstein 0.68%
8TIAA 0.52%
9Hartford 0.52%
10Federated Hermes 0.42%
Institutional-manager reports: top Viridian Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.26%
2State Street 4.50%
3Fairmount Funds Management LLC 3.80%
4Venrock Adviser, LLC 3.65%
5T. Rowe Price 3.25%
6BlackRock 2.95%
7Wellington 2.43%
8GEODE CAPITAL MANAGEMENT, LLC 2.27%
9Novo Holdings A/S 1.94%
10Deep Track Capital, LP 1.84%

Reported Viridian Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Viridian Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Fairmount Funds Management LLC17,201,800 16.69%Schedule 13D, filed May 13, 2026
Entities affiliated with Fairmount Funds Management LLC16,025,330 15.55%Proxy statement (DEF 14A), table as of March 31, 2026
Entities affiliated with FMR LLC7,625,542 7.40%Proxy statement (DEF 14A), table as of March 31, 2026
Bellevue Group AG6,726,144 6.53%Schedule 13G, filed May 15, 2026
Paradigm BioCapital Advisors LP6,723,788 6.52%Schedule 13G, filed August 14, 2026
STATE STREET CORPORATION6,124,976 5.94%Schedule 13G, filed August 7, 2026
T. Rowe Price Associates, Inc.5,748,426 5.58%Schedule 13G, filed August 14, 2026
Point72 Asset Management, L.P.5,687,507 5.52%Schedule 13G, filed August 20, 2026
Deep Track Capital, LP3,592,740 3.49%Schedule 13G, filed August 14, 2026
Stephen Mahoney1,016,882 0.99%Proxy statement (DEF 14A), table as of March 31, 2026

Percentages above are of 103,074,740 shares outstanding, as reported by Viridian Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Viridian Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 238 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,899 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Viridian Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viridian Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Viridian Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Viridian Therapeutics (VRDN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/viridian-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.